epirubicin + dexamethasone

Epirubicin + dexamethasone is a chemotherapy combination composed of the anthracycline antineoplastic agent epirubicin and the synthetic glucocorticoid dexamethasone, used as part of multi-drug regimens for malignancies such as multiple myeloma, breast cancer, and non-Hodgkin lymphoma. Epirubicin intercalates into DNA and inhibits topoisomerase II, generating DNA strand breaks and free radicals that disrupt replication and transcription, leading to apoptosis in rapidly dividing tumor cells. Dexamethasone binds cytosolic glucocorticoid receptors to modulate gene transcription, exerting potent anti-inflammatory, lympholytic, and antiemetic effects, and enhancing the cytotoxic activity of co-administered chemotherapy while helping control treatment-related nausea and hypersensitivity. In practice, this two-drug combination is often embedded within broader regimens (for example with bortezomib or other cytotoxics) rather than used as a stand‑alone fixed-dose product.